In the one quarter several long-term procrastinators all of a sudden realised they would like to work with us.
Which just happened to occur at around the same time as a heads of terms with the global leader in lateral flow POC.
Simple big boy validation. The herd has faith the big boy has spent the time and $$$ testing the tech. A classic case of "if it's good enough for them it's good enough for me" ensues. It's how these things play out in the bio game (and good business sense). The early adopter gets the head start in the market but that head start comes at the cost of R & D $$$.
Buy now and be commensurately rewarded or wait until the signing and be commensurately rewarded. Either way I'm comfortable risking the 10% chance the deal won't go ahead in order to get the extra 100%+ profit. As far as risk-reward plays go there's really no better out there than ADO right now.
ADO Price at posting:
16.5¢ Sentiment: LT Buy Disclosure: Held
